GlassScriptPhysician profile
Steven B Vidrine
NPI 1720125511
$4,265.15
in general payments reported to CMS, 2019-2025
36 companies · $667 in 2025
The $667 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $319 · 2021: $508 · 2022: $757 · 2023: $783 · 2024: $593 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.16 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $427.32 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.04 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Allergan, INC. | $329.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.93 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $198.18 | 2019-2025 | Mounjaro, Zepbound |
| Neos Therapeutics, LP | $184.54 | 2019-2020 | |
| Axsome Therapeutics, INC. | $143.46 | 2022-2025 | Auvelity |
| Glaxosmithkline, LLC. | $135.21 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $123.36 | 2019-2025 | Farxiga, Breztri |
| Supernus Pharmaceuticals, INC. | $91.36 | 2021-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $89.43 | 2020-2021 | |
| Shire North American Group INC | $85.26 | 2019 | |
| Ironshore Pharmaceuticals INC. | $82.35 | 2019-2022 | |
| Pfizer INC. | $73.44 | 2019-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Vidrine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.